New Hope for Knee Osteoarthritis Patients: Relief Without Joint Replacement Surgery

1. What question did you want to answer, what were you particularly interested in? 

Knee osteoarthritis is one of the greatest global health challenges and one of the most common causes of physical disability of the elderly. At the same time, for many of our patients the established conservative measures simply are not enough, while joint replacement is either not (yet) an option or not desired. This is exactly the treatment gap that we address with genicular artery embolization (GAE). What I was particularly interested in was whether the embolic agent used in this study, which is standardized in size and behavior and therefore well controllable, would allow us to establish a reproducible and safe therapy. With this publication we also present, for the first time, a standardized and structured procedural protocol for the method. Beyond that, we were focused on the broader question of how GAE can be established as a reliable treatment option for a very large and heterogeneous patient population. 

2. What specific challenges did you face when developing your approach? 

The central challenge was careful patient selection. Knee pain is multifactorial, and not every cause of pain is amenable to an endovascular therapy. From the outset we therefore worked very closely with the Department of Orthopedics and Trauma Surgery and discussed every case in an interdisciplinary board. On top of that come the technical demands of the procedure itself. The genicular arteries are very small and anatomically variable vessels, and embolization requires a high degree of precision to target the pathological hypervascularity without affecting healthy tissue. The structured, prospective collection of patient reported outcomes over twelve months was also a substantial logistical effort that was only possible thanks to a well coordinated and dedicated study team. Behind a publication like this there is always an entire team, and my sincere thanks go to all colleagues who carried this work forward with great personal commitment and care. 

3. What surprised you and why? What was new? 

What surprised us most was the early onset and the consistency of the pain reduction. The median pain score on the numerical rating scale dropped from 7 to 3 and remained stable throughout the entire follow up year. I find it equally striking that using this score, 80 percent of our patients achieved clinically meaningful improvements. What is new about this work is mainly the size and the systematic design of this prospective cohort with an embolic agent for which very little clinical data had previously existed. The study thereby fits into a growing field of musculoskeletal embolization, in which Charité plays a leading role even beyond this particular work. The BIH Charité Clinician Scientist Program provides precisely these opportunities. 

4. What significance could this success have for future patients? 

For many patients with knee osteoarthritis there is a real treatment gap today. Conservative measures such as intraarticular injections no longer provide sufficient relief, but joint replacement is not an option for medical, personal or biographical reasons. GAE can serve as a safe and comparatively straightforward bridge that reduces pain and improves joint function. With every well documented cohort study the evidence base for this therapy grows, and the more broadly we establish it, the easier access becomes for people who today often live with chronic knee pain for years. 

5. Where do you see the translational bridge between research and application? 

For us, the most important bridge is not built around a single procedure but around the structures we have created and continue to expand. Together with the Department of Orthopedics and Trauma Surgery, with further clinical partners and with research institutions around the world, we are building a cluster at Charité that focuses specifically on minimally invasive musculoskeletal embolization procedures. On the scientific side, the Berlin Institute of Health (BIH) is a crucial partner for us, because it enables exactly this transition between basic research, translational science and clinical application. The result is an environment in which mechanistic questions, study design and patient care go hand in hand, and that, in my view, is the real translational bridge.